What's Next for Nuvilex Inc (OTCMKTS:NVLX)? – MicroCap Daily

Nuvilex Inc (OTCMKTS:NVLX) just dropped south of $0.20 support on accelerated volume. Speculators are salivating as it gets cheaper; everyone remembers the EPIC run that NVLX made from $0.10 to over $0.60 a share earlier this year.
Back in 2011 NVLX acquired a number of assets from SG Austria Private Limited that would change the Company forever and become the thesis of their business plan going forward.
Nuvilex Inc (OTCMKTS:NVLX) is a clinical stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon their unique, proprietary and patented cellulose-based live cell encapsulation technology known as Cell-in-a-Box®.
The live-cell encapsulation technology employed by Nuvilex is a way to enclose living cells in protective “cocoons” about the size of the head of a pin. Each capsule can enclose approximately 10,000 cells and the technology is considered a “platform” upon which treatments can be developed.
Dr.Mark Rabe, chairman of the advisory board of Nuvilex subsidiary, Medical Marijuana Sciences (MMS) summed it up perfectly when he said ”The live cell encapsulation platform employed by Nuvilex is a unique patented technology on which treatments can be developed for deadly and debilitating diseases such as cancer and diabetes. The technology has shown to be successful in the treatment of pancreatic cancer in initial clinical trials using the conventional chemotherapy drug ifosphamide. ”
To get a sense of just how valuable Nuvilex technology could be, consider a recent report published by U.S. based market research company, Transparency Market Research “ the global diabetes devices and drugs market was valued at USD 54.04 billion in 2012 and is estimated to reach a market worth of USD 83.0 billion in 2019 growing at a CAGR of 5.9% from 2013 to 2019.
Many investors in the Company view Nuvilex Cell-in-a-Box® cell encapsulation technology as THE future of diabetes treatment and suggest the Company is a prime buy out candidate from a major such as Bayer who may be closely watching NVLX.
To Find out the inside Scoop on NVLX Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
NVLX has benefited from the Marijuana connection; the sector, although it has cooled significantly has been seriously hot with weed legalized in Alaska, Oregon and Washington DC, Colorado and Washington state.

Nuvilex subsidiary, Medical Marijuana Sciences, Inc., is exploring the benefits of using the Cell-in-a-Box(TM) technology in optimizing the anticancer …Read More